Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HC1902 vs Cleviprex in hypertensive emergencies and urgencies
CTR20230762Phase 3Completed
- Sponsor
- CSPC Zhongnuo Pharmaceutical
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of clevidipine in hypertensive emergency, hypertensive urgency and hypertension (HTN) (2 arms), sponsored by CSPC Zhongnuo Pharmaceutical. Primary endpoint: Proportion of subjects achieving target systolic blood pressure within 30 minutes. Started Mar 2023; status: completed.
02
Drugs
clevidipine
03
Conditions
hypertensive emergencyhypertensive urgencyhypertension (HTN)
Beyond the preview
Go deeper on CTR20230762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230762.